Biosimilar DTC Outlook—Is 2020 the Year of Opportunity?
29 January 2020
Evoke
“With momentum in Washington and increased advocacy from patients and payers, this could be the year of opportunity biosimilar manufacturers have been waiting for.” – Jeff Greene, VP, Strategy
View the full article here
Back to News